- Dentsply Sirona Inc's XRAY Q1 FY22 sales decreased 6.1% Y/Y to $965 million, missing the consensus of $988.43 billion.
- Adjusted EPS decreased to $0.52 from $0.72 a year ago and missed the consensus of $0.56.
- "The first quarter was a challenging quarter, and our financial performance and revised outlook reflect the impact of larger-than-expected macroeconomic headwinds and lower-than-expected performance in the United States.," said John Groetelaars, Interim CEO.
- Technologies & Equipment sales decreased 5.4% (-0.5% organic) to $565 million, driven by supply chain constraints and a weaker sales performance in the U.S., partially offset by continued growth in dentist-directed clear aligners and Implants.
- Consumables sales declined 7.1% to $400 million, and organic sales fell 2.7%, driven by a weaker sales performance, the impact of COVID-19 variants on sales volumes in certain markets, supply chain constraints, partially offset by increased pricing and demand for Endodontic Consumables.
- Operating cash flow reached $93 million.
- Guidance: For FY22, Dentsply Sirona expects organic sales growth of 2% - 3%, with net sales of $4.1 billion - $4.2 billion, versus the consensus of $4.23 billion.
- Earlier, the company expected sales growth of 4% - 5%, with sales of $4.3 billion - $4.4 billion.
- The adjusted operating income margin is expected to be greater than 17% (earlier 21%).
- The company forecasts adjusted EPS of $2.35 - $2.55, down from the prior outlook of $3.05 - $3.25 and the consensus of $2.77.
- Price Action: XRAY shares are down 6.89% at $36.55 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
